Search Results 341-350 of 15941 for SC

  1. A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Conventional Therapies But Have Not Failed Biologic Therapy - Mayo Clinic

    ... SC dose at Week 2 [or one 80 mg SC dose at Baseline, followed by one 40 mg SC dose at Week 2, in countries where this dosing regimen is approved]); OR; At ...

  2. A Study to Assess the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment - Mayo Clinic

    ... SC dose at Week 0, followed by one 40 mg SC dose at Week 2, in countries where this dosing regimen is approved]);; At least one 4-week induction regimen ...

  3. Regenerative Nephrology Compassionate Use Program - Division of Nephrology and Hypertension - Mayo Clinic Research

    Saad A, Dietz AB, Herrmann SMS, Hickson LJ, Glockner JF, McKusick MA, Misra S, Bjarnason H, Armstrong AS, Gastineau DA, Lerman LO, Textor SC. Autologous ...

  4. A Multi-center, Open-label Extension, Safety Study of Mepolizumab in Subjects With Hypereosinophilic Syndrome (HES) From Study 200622 - Mayo Clinic

    ... (SC) for an additional 20 Weeks after completing the 32 Week study assessments post-randomization, while they continue with their background HES therapy per ...

  5. Publications - Kah Whye Peng, Ph.D. - Mayo Clinic

    ... SC, Rafael G, Tran S, Baum A, Kyratsous CA, Peng KW, Russell SJ. IMMUNO-COV ... Concilio SC, Russell SJ, Peng KW. A brief review of reporter gene ...

  6. Former Spine Surgery Fellow Awarded Prestigious Cervical Spine Research Society Traveling Fellowship - News Archive - Mayo Clinic College of Medicine & Science

    Ilyas Aleem, M.D., M.Sc., was recently awarded the prestigious Cervical Spine Research Society traveling fellowship for 2019.

  7. A Study to Evaluate the Effectiveness and Safety of Risankizumab in Subjects with Moderately-to-Severely Active Ulcerative Colitis - Mayo Clinic

    MTX: ≥ 15 mg/week subcutaneous (SC) or intramuscular (IM); ... At least one 4-week induction regimen of golimumab (200 mg SC at Week 0 and 100 mg SC at Week 2); ...

  8. Adenocarcinoma Clinical Trials - Mayo Clinic Research

    This is a multicenter, open-label, Phase 1 study in participants with colorectal cancer (CRC) or gastric cancer to study the safety and tolerability of SC ...

  9. Publications - Katrina S. Pedersen, M.D. - Mayo Clinic

    ... SC, Tan BR, Wise PE, Silviera ML, Smith RK, Suresh R, Byrnes K, Samson PP, Badiyan SN, Henke LE, Mutch MG, Kim H. Circumferential Resection Margin as ...

  10. Insulin aspart, recombinant (intravenous route, subcutaneous route) - Side effects & dosage - Mayo Clinic

    This medicine is available only with your doctor's prescription. This product is available in the following dosage forms: Solution. Back to top ...